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Antagonism of the complement component
C4 by flavivirus nonstructural protein NS1
Panisadee Avirutnan,1,4 Anja Fuchs,1 Richard E. Hauhart,1
Pawit Somnuke,1,5 Soonjeon Youn,1 Michael S. Diamond,1,2,3
and John P. Atkinson1,2,3
of Medicine, 2Department of Pathology and Immunology, and 3Department of Molecular Microbiology,
Washington University School of Medicine, St. Louis, MO 63110
4Medical Molecular Biology Unit, Department of Research and Development, 5Department of Immunology, Faculty
of Medicine Siriraj Hospital, Mahidol University, Bangkok-noi, Bangkok 10700, Thailand

The complement system plays an essential protective role in the initial defense against
many microorganisms. Flavivirus NS1 is a secreted nonstructural glycoprotein that accumulates in blood, is displayed on the surface of infected cells, and has been hypothesized to
have immune evasion functions. Herein, we demonstrate that dengue virus (DENV), West
Nile virus (WNV), and yellow fever virus (YFV) NS1 attenuate classical and lectin pathway
activation by directly interacting with C4. Binding of NS1 to C4 reduced C4b deposition
and C3 convertase (C4b2a) activity. Although NS1 bound C4b, it lacked intrinsic cofactor
activity to degrade C4b, and did not block C3 convertase formation or accelerate decay of
the C3 and C5 convertases. Instead, NS1 enhanced C4 cleavage by recruiting and activating
the complement-specific protease C1s. By binding C1s and C4 in a complex, NS1 promotes
efficient degradation of C4 to C4b. Through this mechanism, NS1 protects DENV from
complement-dependent neutralization in solution. These studies define a novel immune
evasion mechanism for restricting complement control of microbial infection.
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Abbreviations used: Ab, antibody; BHK, baby hamster
kidney; CHO, Chinese hamster
ovasry; CP, classical pathway;
DENV, dengue virus; DF,
dengue fever; DHF/DSS, dengue hemorrhagic fever/dengue
shock syndrome; E, sheep
erythrocytes; EA, Ab-sensitized
E; fH, factor H; GPS, guinea
pig serum; HRP, horseradish
peroxidase; MCP, membrane
cofactor protein; MFI, mean
fluorescence intensity; sCR1,
soluble complement receptor 1;
WNV, West Nile virus; YFV,
yellow fever virus.

The complement system is an essential component of the innate immune response against microorganisms. It consists of a network of soluble
and cell surface proteins that recognize and
target pathogens. Complement activation controls viral infections through multiple mechanisms, including enhanced B and T cell priming,
release of anaphylatoxins (C3a, C4a, and C5a)
that recruit leukocytes to the site of infection,
production of opsonins (C1q, mannose binding lectin [MBL], C4b, and C3b) that bind
viral particles, and formation of C5b-9 membrane attack complexes that lyse virions and/or
infected cells (for review see Avirutnan et al.,
2008). In response, viruses have evolved strategies to limit recognition by and activation of
the complement cascade, including expression
of surface proteins that bind the Fc domain of
antibodies to prevent C1q-dependent complement activation, secretion of soluble viral proteins that mimic or recruit host complement
regulators, direct incorporation of host complement control proteins on the virion, and
J.P. Atkinson and M.S. Diamond contributed equally to this
paper.
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up-regulation of complement regulatory proteins
on the surface of infected cells (for review see
Lambris et al., 2008).
Dengue virus (DENV) is a single-stranded
positive sense enveloped RNA Flavivirus that
is genetically related to several other major
human pathogens, including West Nile virus
(WNV) and yellow fever virus (YFV). DENV
is a mosquito-transmitted pathogen that causes
clinical syndromes in humans ranging from an
acute self-limited febrile illness (dengue fever
[DF]) to a severe and life-threatening vascular
leakage and bleeding diathesis (dengue hemorrhagic fever/dengue shock syndrome [DHF/
DSS]). Globally, DENV causes an estimated 50
million infections annually, resulting in 500,000
hospitalizations and 22,000 deaths (Morens
and Fauci, 2008). Four serotypes of DENV
circulate, and DHF/DSS is commonly associated with a secondary infection by a different
serotype. Although antibody (Ab)-dependent
© 2010 Avirutnan et al. This article is distributed under the terms of an
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six
months after the publication date (see http://www.rupress.org/terms). After six
months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.
org/licenses/by-nc-sa/3.0/).
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RESULTS
DENV NS1 directly binds to C4/C4b and inhibits classical
pathway (CP) activation
Based on a previous study with WNV NS1 (Chung et al.,
2006a), we hypothesized that DENV NS1 might target the
human complement system to attenuate the host immune
response. An ELISA was used to screen for interactions between DENV NS1 and human complement proteins. Micro
titer plates were adsorbed with purified human complement
proteins (Fig. 1 and not depicted). Serum-free supernatants
from baby hamster kidney (BHK) cells that stably propagate a
794

DENV-2 subgenomic replicon (BHK-DENV2-Rep cells)
and secrete high levels (up to 4 µg/ml) of NS1 (Avirutnan
et al., 2007) and from control BHK cells were added to
complement protein-coated wells. Bound DENV NS1
was detected using specific mAbs (Puttikhunt et al., 2003;
Avirutnan et al., 2007). A strong interaction between DENV
NS1 and C4 or C4b was identified (Fig. 1 A). Reciprocal
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enhancement of DENV infection in Fc receptor-bearing
cells has been proposed to initiate pathogenesis (Halstead,
1988), the mechanism for how vascular leakage occurs
remains uncertain. Cytopathic effects of virulent strains of
DENV, a proinflammatory cytokine storm secondary to exuberant activation of poorly lytic cross-reactive T cells, and
excessive complement activation have been suggested to
contribute to the vascular leakage syndrome (for review see
Clyde et al., 2006).
The 11-kb Flavivirus RNA genome encodes a polypro
tein that is cleaved by viral and host proteases to generate
three structural and seven nonstructural proteins. Flavivirus
NS1 is a 48-kD nonstructural glycoprotein that is absent
from the virion. NS1 is an essential gene as it is a required
cofactor for the NS5 polymerase during viral RNA replication (Mackenzie et al., 1996; Lindenbach and Rice, 1997;
Khromykh et al., 1999). In infected mammalian cells, NS1 is
synthesized as a soluble monomer, dimerizes after posttranslational modification in the lumen of the endoplasmic reticulum,
and is transported to the cell surface and accumulates extracellularly as higher order oligomers, including a hexamer (Flamand
et al., 1999). Soluble NS1 also binds back to the plasma membrane of cells through interactions with specific sulfated
glycosaminoglycans (Avirutnan et al., 2007). DENV NS1 has
been implicated in the pathogenesis of DHF/DSS, although
the mechanism remains uncertain. High levels of NS1 are
detected in the serum of DENV-infected patients and correlate with severe disease (Libraty et al., 2002; Avirutnan et al.,
2006). NS1 has been proposed to facilitate immune complex
formation (Avirutnan et al., 2006); elicit autoantibodies that
react with platelet and extracellular matrix proteins (Falconar,
1997) or damage endothelial cells via Ab-dependent, complement-mediated cytolysis (Lin et al., 2003); and directly
enhance infection (Alcon-LePoder et al., 2005). Recently,
WNV NS1 was shown to attenuate the alternative pathway of
complement activation by binding the complement regulatory protein factor H (Chung et al., 2006a).
Here, we describe a novel immune evasion function of
soluble Flavivirus NS1: specific inhibition of the classical and
lectin pathway of complement activation through a direct
interaction with C4 and C1s. DENV, WNV, and YFV NS1
all limit C4b deposition and classical and lectin pathway C3
convertase activity by enhancing cleavage of C4 through the
recruitment of the complement-specific protease C1s.

Figure 1. Direct binding of DENV NS1 to C4 and C4b. (A) ELISA.
Microtiter plates were coated with BSA, C4, or C4b (5 µg/ml). After incubation with serum-free supernatants from BHK-DENV2-Rep cells or control BHK cells, bound DENV NS1 was detected using DENV NS1–specific
mAbs. Data are the mean ± SD for three independent experiments. Asterisks denote NS1 binding that is statistically different from binding to
background (**, P < 0.005; ***, P < 0.0005). (B–E) Reciprocal co-immunoprecipitation. Serum-free supernatants from BHK-DENV2-Rep or control
BHK cells were incubated with purified C4 (B and D) or C4b (C and E;
20 µg/ml) and Western blots were performed after immunoprecipitation
with anti-DENV NS1 mAb (2G6)–Sepharose (B and C) or anti–human
C4–Sepharose (D and E). Immunoprecipitated material was probed with
a goat polyclonal anti–human C4 Ab or DENV NS1–specific mAb (1F11),
respectively. Subunits and cleavage fragments of C4 and C4b are labeled
to the right of the gel; a 93-kD  chain of C4; 84-kD ’ chain of C4b; and
78-kD  chain of C4 and C4b. Notably, in the starting material of this C4
preparation, 20–30% was C4b. Western blot results are representative of
two or three independent experiments.
Flavivirus NS1 inhibits C4 function | Avirutnan et al.
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co-immunoprecipitation experiments confirmed the NS1 and
C4/C4b interaction (Fig. 1, B–E). However, the interaction
of C4 or C4b and DENV NS1 is noncovalent, as the two
proteins independently migrate at their expected sizes by electrophoresis and Western blot.
The functional significance of the NS1–C4 interaction
was demonstrated in sheep erythrocyte (E) hemolysis assays
in which the CP was activated by rabbit anti–sheep polyclonal Abs (Fig. 2). Each purified complement component

JEM VOL. 207, April 12, 2010

DENV NS1 reduces CP C4b deposition
Next, we confirmed the complement inhibitory activity of
DENV NS1 by measuring C4b and C3b deposition on the
surface of EA. Pre-incubation of DENV NS1 with human
C4 reduced C4b and C3b deposition in a dose-dependent
manner (Fig. 3) and prevented cell lysis (Fig. 2, A–C). As
expected, equivalent amounts of the control protein (BSA)
did not interfere with C4b and C3b deposition (Fig. 3). To
test if soluble NS1 also attenuates complement deposition
on the cell surface of nucleated mammalian cells, we used an
established Chinese hamster ovary (CHO) cell model system of complement activation (Barilla-LaBarca et al., 2002;
Liszewski et al., 2008). Cells were sensitized with a polyclonal
Ab against CHO cell surface antigens and the magnitude of
C4b and C3b deposition was monitored by flow cytometry.
Purified human CP complement components (C1, C4, C2,
and C3) were preincubated with DENV NS1 in solution and
subsequently added to Ab-sensitized CHO cells. As expected,
DENV NS1 but not BSA decreased the amount of C4b and
C3b deposited on the CHO cell surface (Fig. 3, E and F).
Based on the above experiments, DENV NS1 downmodulated CP-induced lysis of EA via a direct interaction
with C4 through one of several possible mechanisms: (a) inhibit
ing C4 cleavage by C1; (b) preventing C4b attachment to the
target cell surface; (c) preventing the CP convertase assembly;
795
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Figure 2. DENV NS1 inhibits C4 to prevent CP dependent hemolysis. (A and B) Human C4 was incubated in the presence or absence of
DENV NS1 and then added to sensitized EA bearing C1 (EAC1). After three
washes, the EAC14b cells were incubated with purified C2, washed, and
incubated with GPS treated with EDTA (A) or purified human components
(B; C3-C9) at 37°C for 30 min. After centrifugation, the supernatant was
analyzed by spectrophotometry at 414 nm. (C) Single-step hemolysis
assay. EA were incubated with an 80-fold dilution of C4-deficient GPS that
was supplemented with human C4, with or without preincubation with
DENV NS1. The data represent the mean ± SD for three independent experiments. Asterisks denote hemolysis conditions that are statistically
different from untreated cells (*, P < 0.05; **, P < 0.005; ***, P < 0.0005).

was sequentially added to Ab-sensitized E (EA) in the presence or absence of DENV NS1. Preincubation of purified
DENV NS1 with human C4, but not with C1, C2, or C3
(unpublished data) interfered with hemolysis in three different assays in which the complement proteins were limiting:
(a) addition of purified components C1, C4, and C2 to EA
(EAC14b2a) followed by an incubation with a 20-fold dilution of guinea pig serum (GPS) as the source of C3 and
terminal complement components (C5-C9) in an EDTA
containing buffer (GPS-EDTA; Fig. 2 A); (b) sequential addition of purified human C1-C9 to EA, in which purified
C3-C9 was added to EAC14b2a instead of GPS-EDTA (Fig.
2 B); and (c) a single-step hemolysis assay in which EA were
incubated with an 80-fold dilution of C4-deficient GPS
supplemented with human C4 that had been preincubated in
the presence or absence of DENV NS1 (Fig. 2 C). The specificity of DENV NS1 for inhibiting hemolytic activity was
confirmed in preclearance experiments (Fig. S1 A) as follows:
preincubation of DENV NS1 with anti-NS1 (2G6)– but
not anti-E (4G2)–Sepharose abolished the inhibitory effect
(Fig. S1 B). Notably, the amount and inhibitory activity of
DENV NS1 after the preclearing step with 4G2–Sepharose
was similar to that observed with a 1:2 dilution of starting
material. The concentrations of NS1 used in these studies
have been observed in plasma and pleural fluid of human
patients infected with severe DENV infection (Alcon et al.,
2002; Libraty et al., 2002; Avirutnan et al., 2006). Collectively, these functional experiments suggest that DENV NS1
specifically inhibits CP-induced lysis of targets via an interaction with C4.
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(d) inhibiting CP convertase formation and stability; or (e) promoting C4 degradation in solution.
DENV NS1 lacks the ability to regulate the CP convertases
A common mechanism for pathogens to evade human complement is to inactivate the central proteolytic enzymes, the

C3 and C5 convertases (point c and d in the previous section;
Lambris et al., 2008). To test whether DENV NS1 had
this activity, we again used a hemolysis assay. In contrast to a
soluble complement regulator, C4 binding protein (C4BP),
which interferes with CP convertase assembly (Gigli et al.,
1979), incubation of DENV NS1 with C1- and C4-treated

Downloaded from jem.rupress.org on September 13, 2011
Figure 3. DENV NS1 reduces C4b and C3b deposition on the surface of cells. Human C4 was incubated with serially diluted purified DENV NS1 or
BSA (12.5, 25, or 50 µg/ml) for 1 h before adding EAC1. After a 15-min incubation at 30°C, EAC14b were sequentially incubated with C2 and C3. After
three washes, the deposition of C4b (A and C) and C3b (B and D) was determined by incubating EAC14b2a3b with anti-C4c or anti-C3c mAb, and analyzed
by flow cytometry. Examples of histogram profiles in which DENV NS1, but not BSA, blocks C4b (A) and C3b (B) deposition are depicted. In C and D, data
are expressed as the specific mean fluorescence intensity (MFI) of staining. The error bars indicate SD corresponding to three independent experiments.
Asterisks denote C4b or C3b deposition that is statistically different from untreated cells (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). (E and F) Soluble DENV
NS1 restricts complement deposition on the surface of nucleated cells. CHO cells were sensitized with rabbit anti-CHO surface antigen IgG before incubation with the mixture of DENV NS1 or BSA (25 µg/ml) and purified human CP complement components C1, C4, C2, and C3, followed by immunostaining
with murine mAb to human C4d (E) and C3d (F) and analyzed by flow cytometry. EDTA (20 mM) was added to inhibit complement activation for negative
controls. Examples of histogram profiles from three independent experiments in which DENV NS1, but not BSA, restricted C4b (E) and C3b (F) deposition
are shown.
796
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EA (EAC14b) before adding C2 did not inhibit hemolysis
(Figs. S1 and S2 A). The same result was obtained if CP C3
(C4b2a) or C5 (C4b2a3b) convertase was used; thus, incubation with DENV NS1 did not alter lytic activity whereas
addition of the human regulators soluble complement re
ceptor 1 (sCR1) and C4BP readily dissociated the convertases and inhibited the CP-induced hemolysis (Fig. S2,
B and C). Therefore, although DENV NS1 binds C4b,
it does not prevent convertase assembly or possess decayaccelerating activity.

WNV NS1 also inhibits CP activation via a direct
interaction with C4
We extended our study to test whether other Flavivirus NS1
proteins retained this complement inhibitory function. Notably, WNV and YFV NS1 efficiently bound human C4 and
C4b (Fig. 4 A), but only WNV NS1 inhibited CP activation
to a similar extent compared with DENV NS1 (Fig. 4 B).
Inhibition of CP activation and complement-dependent he
molysis by DENV and WNV NS1 was observed with C4 from
guinea pig (Fig. 4 C) or human serum (Fig. 4 D).
DENV and WNV NS1 promote cleavage
of hemolytically active C4
To determine the mechanism for how NS1 inhibits CPmediated complement activation, we assessed the efficiency
of C4 cleavage by C1s in the fluid phase in the presence and
absence of NS1. The ratio of the  and  chain of C4 and
C4b was analyzed by Western blot. If NS1 acted by inhibiting C4 cleavage by C1s, we would expect greater amounts of

Figure 4. DENV and WNV NS1 inhibit CP activation via a direct interaction with C4. (A) DENV, WNV, and YFV NS1 interact with human C4/C4b.
Microtiter plates were coated with BSA, C4, or C4b (5 µg/ml). After incubation with purified DENV, WNV, or YFV NS1 (5 µg/ml), bound NS1 was detected
using DENV, WNV, or YFV NS1-specific mAbs. (B) EA were incubated with a 160-fold dilution of C4-deficient GPS that was supplemented with purified
human C4 (63 ng/ml), with or without preincubation with DENV, WNV, or YFV NS1 or BSA (12.5–50 µg/ml). (C and D) DENV and WNV NS1 inhibit
C4-mediated CP in guinea pig and human sera. EA were incubated with a 160-fold dilution of C4-deficient GPS that was supplemented with the
indicated dilutions of fresh guinea pig (C) or human serum (D), with or without preincubation with DENV or WNV NS1 (50 µg/ml). Data are the mean ±
SD for three independent experiments. Asterisks denote NS1 binding that is statistically different from binding to background (A) or hemolysis
conditions which are statistically different from untreated cells (B–D; *, P < 0.05; **, P < 0.005; ***, P < 0.0005).
JEM VOL. 207, April 12, 2010
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DENV NS1 lacks cofactor activity for factor
I to degrade C4b
Experiments were performed in the fluid phase to test
whether NS1-modulated cofactor activity by augmenting the
ability of factor I to degrade C4b in solution. Purified DENV
NS1 was incubated with C4b, followed by sequential addition of factor I, with or without a known cofactor. Subsequently, C4b cleavage products were identified by Western
blot using anti–C4d-specific mAbs. In contrast to the established cofactors C4BP, membrane cofactor protein (MCP),
and CR1, addition of DENV NS1 did not enhance the

protease activity of factor I for C4b; thus, NS1 lacks intrinsic
cofactor activity for factor I (Fig. S3).

Published March 22, 2010

C4- compared with C4b- chain. Instead, preincubation
of DENV NS1 with C4, before addition of C1s, increased
the generation of the C4b- chain (Fig. 5 A). This result was
initially surprising to us because, if NS1 promoted C4b-
chain accumulation on the erythrocyte cell surface, it should
have enhanced hemolysis. However, a loss of C4- chain
and accumulation of C4b  chain was also observed in the

798

C1s/C1s proenzyme copurifies with WNV and DENV NS1
Because the complement protease C1s is blocked by
C1-INH (Ziccardi, 1982) and is synthesized and secreted by
a variety of cell types (Thielens and Arlaud, 2000), we evaluated whether hamster (from BHK cells) C1s copurified with
NS1. Initially, a two-step purification was performed to generate highly purified preparations of NS1 (Avirutnan et al.,
2007). The elution profile of affinity-purified WNV NS1
(first column) followed by ion-exchange (second) column
displays a heterogeneous profile (Fig. 6 A), which is likely
caused by the presence of oligomers of soluble NS1 (Flamand
et al., 1999; Fig. S5). The heterogeneity in size was confirmed by size exclusion chromatography (Fig. 6 F and Fig. S6).
After purification, each fraction of NS1 was tested for C4
inhibitory activity in the hemolysis assay, as well as the presence of hamster C1s by Western blot with a cross-reactive
anti–human C1s polyclonal Ab. After separation by ionexchange chromatography, all fractions of WNV NS1 had
C4 inhibitory activity, with the exception of the main peak
fractions (B8-B10; Fig. 6 B). In our functional experiments
(Figs. 2–5), high concentrations of NS1 (20–50 µg/ml) were
required to inhibit hemolysis. However, when the fraction
with peak activity (fraction C1; Fig. 6, A and B) was serially
diluted and subjected to the C4 hemolysis assay, the specific
C4 inhibitory activity was observed at a much lower con
centration of NS1 (1.75 µg/ml; Fig. 6 C). Hamster C1s was
detected in most of the fractions of purified WNV NS1 that
had C4 inhibitory activity, but not in the NS1 fractions that
lacked activity (Fig. 6 D). Correspondingly, the fractions of
WNV NS1 after size exclusion chromatography that exhibited inhibitory activity in the C4 hemolysis assay (Fig. 6,
F and G) also had detectable levels of C1s (Fig. 6 H). Although
similar results were observed with DENV NS1, hamster C1s
Flavivirus NS1 inhibits C4 function | Avirutnan et al.
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Figure 5. Purified DENV NS1 and WNV NS1 promote C4 cleavage.
(A and B) Western blot analysis. (A) Purified DENV NS1, WNV NS1, BSA, or
lysozyme (50 µg/ml) was preincubated with C4 (6.25 µg/ml) for 1 h on ice.
Subsequently, the NS1-C4, BSA-C4, and lysozyme-C4 solutions were incubated at 30°C for 15 min. (B) Purified C4 was incubated with C1s (12 µg/ml)
for 1 h at 30°C. Subunits and cleavage fragments of C4 and C4b are
labeled to the right of the gel; 93 kD  chain of C4; 84 kD ’ chain of C4b.
(C and D) Inhibition of C4 cleavage in the presence of NS1 by C1 inhibitor
(C1-INH). (C) C4a ELISA. C4 was incubated with purified DENV NS1 or
lysozyme (30 µg/ml) in the presence or absence of C1-INH (1.4 µg/ml) on
ice for 1 h. (D) Single-step hemolysis assay. EA were incubated with a
160-fold dilution of C4-deficient GPS supplemented with human C4
(0.1 µg/ml) that was preincubated with DENV or WNV NS1 (30 µg/ml) in
the presence or absence of C1-INH (40 µg/ml). In some experiments, C1
inhibitor (C1-INH; 40 µg/ml) was added to before the incubation with
EA- and C4-deficient GPS. Data are the mean ± SD for four independent
experiments. Asterisks denote C4a liberation (C) as measured by ELISA
that is statistically different (**, P < 0.005) or hemolysis conditions (D)
that are statistically different from untreated cells (***, P < 0.0005).

absence of C1s when C4 was incubated with WNV NS1 but
not with control proteins, BSA or lysozyme (Fig. 5 A); thus,
NS1-dependent C4 cleavage in the fluid phase was analogous
to that observed with C1s (Fig. 5 B). Cleavage of C4 in the
presence of NS1 was also confirmed by detection of the small
fragment C4a (Fig. 5 C). Nonetheless, C4 cleavage in the
presence of NS1 was specific; incubation of purified C3 with
NS1 did not result in degradation of the C3  chain, even
after prolonged incubation at 37°C (Fig. S4).
Because NS1 sequence does not encode any known
protease motifs, one possibility was that the C4 but not C3
cleavage activity was caused by C4-specific proteases that
copurified with NS1. To evaluate this, we assayed whether
protease inhibitors could block NS1-dependent cleavage of
C4. Among the protease inhibitors tested including phenylmethylsulfonylfluoride and commercial protease inhibitor
cocktails (data not shown), the NS1-dependent C4b 
chain accumulation was most efficiently inhibited by the
plasma serine protease inhibitor, C1 inhibitor (C1-INH;
Fig. 5 C). Correspondingly, C1-INH also abrogated C4
inhibitory activity of WNV and DENV NS1 in hemolysis
assays (Fig. 5 D).
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was not detected in purified fractions of YFV NS1 (not
depicted); consistent with this, YFV NS1 bound C4, but did
not inhibit in the hemolysis assay (Fig. 4 B).
C1s is synthesized as a single 80-kD chain proenzyme
(proC1s) and activated after cleavage of a single peptide bond
between amino acids R437 and I438, yielding a disulfidelinked 52-kD  chain and 28- kD  chain (Thielens and
Arlaud, 2000). Reducing SDS-PAGE and Western blot analysis of the hamster C1s that copurified with NS1 revealed

three distinct bands corresponding to the  and  chains of
activated C1s and proC1s. In contrast, only a single band of
proC1s was observed in a concentrated (100-fold) serum-free
culture supernatant from uninfected BHK cells (Fig. 6 E).
Autocatalytic activation of proC1s independent of its activator C1r has been previously shown (Morgan and Nair, 1975).
ProC1s may have become auto-activated during the purifi
cation process or alternatively, binding of NS1 to proC1s
induced autocatalysis.

Downloaded from jem.rupress.org on September 13, 2011

Figure 6. C1s/proC1s copurifies with NS1. (A) Two-step purification of WNV NS1. Immunoaffinity-purified WNV NS1 was passed over an ione xchange column, and NS1 was eluted with a linear NaCl gradient (diagonal line). Silver stain and Western blot of each fraction were performed (Fig. S5 and
not depicted). All fractions were tested for C4 inhibitory activity in a single-step hemolysis assay (B). C4 (0.1 µg/ml) was preincubated with an individual
concentrated fraction (25 µl) before the addition of EA- and C4-deficient GPS (1:160). Fractions with C4 inhibitory activity are bracketed (A and B).
(C) WNV NS1 fraction #C1 from ion exchange chromatography was twofold serially diluted and subjected to a single-step C4 hemolysis assay.
(D and E) Western blot analysis for C1s/proC1s from ion exchange fractions shown in A. (D) Nonreduced SDS-PAGE. Lane 1, 100-fold concentrated serumfree culture supernatants (SFM) of BHK cells; lanes 2–7, 10-fold concentrated purified WNV NS1 fractions after ion-exchange chromatography. The proteins were separated on a 4–12% gradient nonreduced SDS-PAGE, transferred, and probed with a goat anti–human C1s serum. The anti–human C1s Ab
cross-reacts with hamster C1s. (E) SDS-PAGE, reducing conditions. Lane 1, 100-fold concentrated SFM of BHK cells; lanes 2 and 3, purified human C1s
(huC1s) and human proC1s (huProC1s; 10 ng); lanes 4–8, 10-fold concentrated purified WNV NS1 fractions after ion-exchange chromatography. (F) Size
exclusion chromatography profile of affinity-purified WNV NS1. Molecular sizes of indicated fractions were calculated from a set of protein standards
loaded on the same column. (G) Size exclusion chromatography fractions were collected, concentrated 10-fold, and subjected to a single-step hemolysis
assay as described in B, as well as a nonreduced SDS-PAGE and Western blot with anti–human C1s Ab (H). Brackets denote the fractions that inhibit
C4-dependent hemolysis (F and G). Results are representative of two or three independent experiments.
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also observed (Fig. 7, C and F, and Fig. S6 B), suggesting
an avid interaction. Based on the column migration patterns, we postulated a direct interaction between NS1 and
C1s/proC1s. Binding assays confirmed that DENV, WNV,
and YFV NS1 directly interacted with human C1s and
proC1s (Fig. 7, G and H).
Although all of our experiments suggested that NS1 could
interact with both C4 and C1s to limit complement activation, an underlying concern was that the interaction with
C1s was still nonspecific. We reasoned that a nonspecific
interaction should not affect the inherent enzymatic activity
of C1s. However, if NS1 enhanced the C4 cleavage activity
of C1s, it would strongly support the concept of a specific
functional interaction. We evaluated this hypothesis using a
modified hemolysis assay. Purified NS1 was preincubated
with human C1s or proC1s before the addition of human
C4; subsequently, C4-deficient GPS was added to sensitized

Figure 7. Flavivirus NS1 directly binds to C1s/proC1s. (A–F) Size-exclusion chromatography. Purified huProC1s (A) or Fab fragment of murine mAb
to WNV E (E9-Fab; D) or the mixture of huProC1s + WNV NS1 (B and C) or E9-Fab + WNV NS1 (E and F) were fractionated by size exclusion chromatography. Fractions were concentrated 10-fold, separated on SDS-PAGE under reducing (A–C) or nonreducing (D–F) conditions and immunoblotted with goat
antiserum to huC1s (A and B), goat anti–mouse IgG (D and E), or mouse anti-WNV NS1 (C and F). Subunits of C1s are labeled to the right of the gel; an
85-kD subunit of huProC1s or huC1s; a 52-kD  chain of huC1s; and a 23-kD  chain of huC1s. Of note, a subset of proC1s was activated during the
fractionation to become C1s (A and B). Results are representative of two independent experiments. (G and H) ELISA. Microtiter plates were coated with
purified BSA and huC1s (G) or BSA and huProC1s (H). After incubation with affinity-purified DENV, WNV, or YFV NS1, bound NS1 was detected using
DENV-, WNV-, or YFV NS1–specific mAbs, respectively. Specific binding was calculated by subtracting the OD in antigen-coated wells from the OD. in
BSA-coated wells. Data are presented as the mean ± SD for three independent experiments.
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Flavivirus NS1 directly binds C1s/C1s proenzyme
and enhances cleavage of C4
As our data suggested a separate biochemical interaction between NS1 and C1s, experiments were performed to test if
NS1 physically interacted with C1s and C1s proenzyme.
Purified human proC1s, WNV NS1, or mixtures of both
were separated by size exclusion chromatography. When
proC1s was run alone, Western blot analysis showed that it
was present exclusively in fractions B9 and B10 (Fig. 7 A).
When the same amount of proC1s was preincubated with
WNV NS1, it distributed more broadly over the fractions
that contain WNV NS1 (Fig. 7, B and C). Importantly, the
distribution of a Fab fragment of similar size but irrelevant
specificity did not change when mixed with WNV NS1
(Fig. 7, D and E). Additionally, a change in the distribution pattern of size exclusion chromatography fractions that
contained WNV NS1 after binding to human proC1s was

Published March 22, 2010

Ar ticle

NS1 protects Flaviviruses from complement attack
Complement can directly neutralize Flavivirus virions and
infectivity (Mehlhop et al., 2005) in vitro and has a protective
role in restricting WNV infection in mice. Because Flavivirus
NS1 antagonizes C4 and subsequent C3 deposition, we hypothesized that soluble NS1 that accumulates to high amounts
(up to 50 µg/ml) in serum (Alcon et al., 2002) could protect
DENV from direct complement-mediated neutralization. As
expected, DENV was efficiently neutralized by naive wild
type GPS (Fig. 9 A). In contrast, C4-deficient GPS or heatinactivated wild-type serum failed to diminish DENV infectivity, confirming a complement-dependent neutralization
mechanism (Fig. 9, A and B). Addition of purified human C4
to guinea pig C4-deficient serum restored the ability to neutralize DENV infection in a dose-dependent manner (Fig. 9 B).
Importantly, the addition of soluble DENV NS1 (Fig. 9 B) or
WNV NS1 (not depicted), but not BSA, rescued infectivity.
This antagonistic effect of NS1 was C4-dependent, as addition of higher concentrations of human C4 overcame the
inhibition of GPS neutralization by NS1. Although one study
suggested that pretreatment of cells with soluble DENV NS1
before infection of hepatoma cells improves virus yield twofold (Alcon-LePoder et al., 2005), we did not observe this
phenomenon; when NS1 was added alone or mixed with
heat-inactivated serum, no changes in infectivity were observed (Fig. 9 B and not depicted). Collectively, these studies
demonstrate that soluble NS1 can antagonize C4 function,
which affects viral infection.
DISCUSSION
Viruses have evolved strategies to avoid recognition and destruction by the complement system (for review see Lambris
et al., 2008). WNV NS1 has previously been shown to attenuate alternative pathway activation by recruiting complement
regulator factor H to facilitate C3b inactivation by factor I
(Chung et al., 2006a). Herein, we define a novel mechanism
in which NS1 restricts classical/lectin pathway activation by
targeting C4. Binding of soluble NS1 to proC1s/C1s and C4
JEM VOL. 207, April 12, 2010
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sheep EA. Higher concentrations of C4 were used in this
assay compared with the previous hemolysis experiments to
overcome the inherent C4 cleavage activity of hamster C1s/
proC1s that copurified with WNV and DENV NS1. Notably, WNV and DENV NS1, but not BSA or lysozyme,
enhanced the activity of C1s and proC1s to cleave C4 as
observed by decreased hemolysis (Fig. 8, A and B). Most importantly, although purified YFV NS1 did not associate significantly with hamster C1s/proC1s to promote degradation
of C4 by itself (Fig. 4 B), it readily bound human C1s/proC1s
(Fig. 7, G and H), which then facilitated cleavage of C4 (Fig. 8,
A and B) in a manner similar to WNV and DENV NS1.
Acceleration of C4 degradation in solution by human proC1s
in the presence of YFV NS1 was confirmed in kinetic experiments (Fig. 8 C). This activity was specific to NS1, as
lysozyme or BSA did not alter the kinetics of C4 cleavage
by proC1s (Fig. 8 C and not depicted).

Figure 8. Flavivirus NS1 enhances ability of C1s and proC1s to
cleave C4. Purified WNV, DENV, or YFV NS1 (20 µg/ml) was incubated
with huC1s (0.04 µg/ml; A) or huProC1s (0.4 µg/ml; B) on ice. After a 1-h
incubation, C4 (5 µg/ml) was added and incubated for 1 h on ice followed
by EA and 160-fold dilution of C4-deficient GPS. (C) YFV NS1 accelerates
C4 degradation by proC1s. Purified YFV NS1 (20 µg/ml) was incubated
with or without huProC1s (0.2 µg/ml) for 1 h on ice followed by the addition of C4 (2.5 µg/ml). At indicated times after incubation at room temperature, EA and 160-fold dilution of C4-deficient GPS were added and
hemolysis was determined. The data represent the mean ± SD for three to
four independent experiments. Asterisks denote hemolysis conditions that
are statistically different from the cells treated with C1s or proC1s alone
(*, P < 0.05; **, P < 0.005; ***, P < 0.0005).
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enhances the cleavage of C4 to C4b in solution, thus decreasing activation by the classical and lectin pathways. The interaction between Flavivirus NS1, C1s, and C4 has functional
consequences, including reduced deposition of C3b and
C4b on virions and target cells and protection of virus from
complement-mediated neutralization.
The targeting of C4 in the context of an NS1 interaction
with proC1s/C1s is a novel evasion strategy to attenuate
classical and lectin pathway activation. Herpesviruses and
coronaviruses interfere with CP activation by secreting or
expressing decoy molecules with Fc receptor function
(Oleszak et al., 1993; Para et al., 1982), whereas Porphyromonas,
Streptococcus, and Staphylococcus bacteria degrade IgG and/or
inhibit IgG interaction with C1q (Björck and Kronvall, 1984;
Schenkein et al., 1995; von Pawel-Rammingen and Björck,
2003). Additionally, the Staphylococcus SCIN and Efb proteins
block CP and alternative pathway C3 and C5 convertases
(Rooijakkers et al., 2005; Jongerius et al., 2007). Mechanistically, NS1 promotes cleavage of C4 in solution, which attenuates generation of C3b and C5b-9 on targets (e.g., virions or
virus-infected cells). An analogous cleavage of C3 to C3blike proteins by extracellular gelatinase has been described as
a mechanism of complement evasion by Enterococcus faecalis
(Park et al., 2008). Our studies do not rule out the possibility
that NS1 also inhibits complement activation by independently preventing C4b attachment to target cells. Unlike
poxviruses, which express viral virulence factors with structural and functional similarities to human complement regulators (Rosengard et al., 2002), NS1 itself lacks any apparent
sequence homology to known complement proteins or
enzymes. Interestingly, C4 is the only complement protein
that is sulfated on a tyrosine residue, and this posttranslational
modification increases the efficiency of C4 cleavage by C1s
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Figure 9. Soluble NS1 protects DENV from complement attack.
(A) Neutralization of DENV by GPS. DENV virions were incubated with
untreated or heat-inactivated (HI) normal GPS for 1 h at 37°C to allow
complement activation. The samples were then added to BHK-21 monolayer, and after agarose overlay, cultured for 5 d. After fixation and staining of wells, plaques were counted. (B) Soluble DENV NS1 protects DENV
from complement C4-mediated neutralization. Purified human C4 at the
indicated concentrations was incubated with soluble DENV NS1 or BSA
(50 µg/ml) or buffer (PBS) alone for 1 h at room temperature. DENV was
then added and followed by untreated or HI C4-deficient C4D GPS. Samples were incubated for 1 h at 37°C before infection of BHK-21 cells, as
described in A. Data are representative of three independent experiments.

(Hortin et al., 1989). As DENV NS1 binds sulfated glycosaminoglycans (Avirutnan et al., 2007), it is tempting to speculate that NS1 binding near the sulfated tyrosine on C4 could
render it more susceptible to C1s or C1s-like proteases.
Investigations with mutant NS1 proteins and C4 lacking
sulfation are planned to directly test this hypothesis.
The presence of C4 protease activity (hamster C1s) in the
WNV and DENV NS1 preparations initially raised the possibility of a contaminant. Several biochemical experiments,
however, suggest that the interaction of Flavivirus NS1
with C1s and C4 is specific: (a) YFV NS1, which does not
copurify efficiently with hamster C1s, binds C4 but lacks
cleavage activity. However, addition of YFV NS1 to limiting
quantities of human proC1s and C1s enhances the cleavage
rate of C4; (b) WNV, YFV, and DENV NS1 all bind directly
to human proC1s and C1s by ELISA; (c) WNV NS1 specifically shifts the size exclusion chromatography profile of
human proC1s. Although our data suggest that NS1 promotes cleavage of C4 by recruiting and enhancing the
enzymatic activity of C1s, it remains unclear mechanistically
how NS1 achieves this. Binding of NS1 to C1s/proC1s may
cause structural changes that increase the proteolytic activity
of C1s. Alternatively, oligomeric forms of NS1 could bring
C4 and C1s together for a sustained interaction that pro
motes cleavage.
Our data showing that NS1 inhibits the classical and
lectin pathways of complement activation appears to contrast
with previous experiments showing that DENV NS1 triggers
accumulation of C5b-9 complexes in human serum (Avirutnan
et al., 2006). This discrepancy may be explained by the presence of natural and neutralizing IgM against NS1 and the
relative concentrations of NS1 and C4 in serum (comparatively low NS1 and high C4) that could attenuate an inhibitory effect on C4 activation. In peripheral tissues where
the majority of Flavivirus infection occurs, higher local levels
of NS1 coupled with lower levels of extravascular complement and Ab concentrations could efficiently inhibit C4
function. Flaviviruses, thus, may use NS1 to bind C1s proenzyme produced from the same infected cell or neighboring
cells to inactivate C4 in solution. By forming a complex with
C1s, NS1 can promote continuous cleavage of C4 to C4b.
In solution, this nascently generated C4b would have only a
few microseconds to bind to a target before further hydrolysis, as observed with activated C4b. Thus, NS1 targeting of
C4 could directly limit opsonization and neutralization of
virions and thereby facilitate local dissemination.
Complement activation has been implicated in the vascular leakage syndrome of severe DENV infection (Bokisch et al.,
1973; Avirutnan et al., 2006) with C4 consumption occurring in patients with DHF/DSS (Bokisch et al., 1973). The
NS1 antagonism of complement function could explain
some of the clinical and pathological findings of severe
DENV disease. However, severe dengue disease usually
occurs after secondary DENV infection by a different viral
serotype. Pre-existing cross-reactive anti-NS1 Abs could
modulate (enhance or inhibit) the ability of DENV NS1 to
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MATERIALS AND METHODS

Purified Flavivirus NS1 and complement proteins
DENV NS1 was produced and isolated as previously described from
DENV2-infected mammalian cells and BHK-DENV2-Rep cells (Avirutnan
et al., 2006, 2007). WNV and YFV NS1 were isolated from supernatants of
BHK-WNV-Rep and BHK-YFV-Rep cells as previously described (Chung
et al., 2006a; Patkar and Kuhn, 2008) or BHK cells infected with recombinant Sindbis viruses encoding Flavivirus NS1. WNV and YFV NS1 were
expressed using the double subgenomic Sindbis virus 39 E2H55K50 (39HK;
Ryman et al., 2007). In brief, the NS1 gene of WNV and YFV including a
24-amino acid signal sequence corresponding to the C-terminus of the E
protein was amplified from infected Vero cells by RT-PCR using the
following oligonucleotide primers (WNV NS1 forward 5-GGGCGGCCGCACCATGGATAGGTCCATAGCTCTCACGTTT-3; WNV NS1
reverse 5-CTGCGGCCGCTAAGCATTCACTTGTGACTGCAC-3;
YFV NS1 forward 5-GCGGCCGCACCATGGACATGACAATGTCC
ATGAGCA-3; YFV NS1 reverse 5-TCAAGCTGTAACCCAGGA
GCGCACCAG-3). WNV and YFV NS1 were subcloned into 39HK after
digestion with NotI and PmeI restriction enzymes. After sequencing,
recombinant 39HK expressing WNV or YFV NS1 (39HK WNV NS1 or
39HK YFV NS1) was produced by SP6 DNA-dependent RNA polymerase
in vitro transcription. DNA templates linearized with XhoI were transcribed
in vitro by SP6 RNA polymerase using mMESSAGE mMACHINE kit
(Ambion) following the manufacturer’s instruction. In vitro–transcribed
RNA was electroporated into BHK cells with 3 consecutive electrical pulses
of 850 V at 25 µF and  Ω using the Gene Pulser Xcell (Bio-Rad Laboratories) and double subgenomic infectious viruses were harvested 2 d later.
WNV or YFV NS1 was harvested from supernatants of BHK cells infected
with 39HK WNV NS1 or 39HK YFV NS1 at a multiplicity of infection
(MOI) of 1 in serum-free DME at 36 h. Infectious recombinant Sindbis
virus was inactivated by -propiolactone treatment at 37°C overnight or
NP-40 (0.05% [vol/vol] final concentration) before NS1 purification using
a Flavivirus cross-reactive anti-NS1 (9NS1; Chung et al., 2006b) Sepharose
4B column. A two-step purification of Flavivirus NS1 was performed as
described previously (Avirutnan et al., 2007) using ion exchange or size
exclusion chromatography.
All purified human complement proteins were purchased commercially
(Complement Technologies) unless otherwise stated. To differentiate
between C1s and proC1s, SDS-PAGE and Western blot analysis were
performed: under reducing (5% -mercaptoethanol) conditions, C1s appears
JEM VOL. 207, April 12, 2010

as two bands (52 kD  chain and 23 kD  chain), whereas proC1s migrates
as an 80-kD single band (see Fig. 6 E). Under nonreducing conditions,
C1s and proC1s both migrate as a single 80-kD band. For each preparation
of proC1s, this type of analysis confirmed the purity of proC1s relative to
C1s. Furthermore, in functional analyses, 10–100–fold more proC1s than
C1s was required to cleave an equal quantity of C4.

NS1 and C4/C4b binding ELISA
Maxi-Sorp microtiter plates were adsorbed with purified C4 or C4b
(5 µg/ml in PBS) at 4°C overnight. After five washes with PBS, nonspecific
binding sites were blocked with 1% heat-inactivated BSA in PBS for 2 h
at room temperature followed by five washes with PBS. Clarified (200 g, 5 min)
serum-free supernatants from BHK or BHK-DENV2-Rep cells were
added to each well and incubated for 2 h at room temperature. Plates
were then washed five times with PBS containing 0.05% Tween-20
followed by a 1-h incubation with a mixture of DENV NS1-specific
mAbs (1A4, 1B2, 1F11, 2G6, and 2E3; 1 µg/ml of each; Puttikhunt
et al., 2003). After washing, biotinylated goat anti–mouse IgG and horseradish peroxidase (HRP)–conjugated streptavidin were added sequentially at room temperature. After six final washes with PBS, signal was
detected by adding 3,3, 5,5-tetramethylbenzidine substrate. Plates were
evaluated on a 96-well plate reader (GENois Pro; Tecan Instruments). In
some experiments, purified NS1 from DENV and WNV (5 µg/ml) was
used instead of crude supernatants. A mixture of WNV NS1–specific
mAbs (10NS1, 14NS1, 16NS1, 17NS1, and 22NS1; (Chung et al., 2006b)
was used to detect WNV NS1.

Immunoprecipitation and Western blot studies
NS1 immunoprecipitation. NS1-containing supernatants were incubated
with human C4 or C4b at 4°C overnight and then immunoprecipitated with
anti-NS1 mAb (2G6)–Sepharose. After five washes, bound proteins were
eluted in SDS reducing sample buffer and separated by 10% SDS-PAGE.
Western blot was performed using goat anti–human C4 Ab (Quidel) and
HRP-conjugated anti–goat IgG (GE Healthcare).
C4 immunoprecipitation. NS1-containing supernatants were incubated with C4 and C4b and immunoprecipitation was performed with
anti–human C4 Ab-coated beads. After five washes, the samples were
boiled in SDS sample buffer and separated by 12% SDS-PAGE. Western
blot was performed using anti-DENV NS1 mAb (1F11) hybridoma
supernatant and HRP-conjugated anti–mouse IgG. Anti–human C4
Ab-coated beads were prepared by adding 5 µg of goat anti–human C4
polyclonal Ab (Abcam) to 50 µl of TrueBlot anti–goat Ig immunoprecipitation beads (eBioscience).

Erythrocyte hemolysis assay
The assay was performed by a stepwise buildup of complement intermediates
on EA according to previous work (Krych-Goldberg et al., 1999). EA were
incubated with C1 (EAC1) for 15 min at 30°C. Before addition to EAC1 cells,
C4 was preincubated with purified DENV NS1 for 1 h on ice. After a 15-min
incubation at 30°C, C1- and C4-treated EA (EAC14b) were washed three
times and incubated with C2 for 4 min at room temperature. C1, C4, and C2
treated EA (EAC14b2) were washed and incubated with a 20-fold dilution
of GPS in 40 mM EDTA containing veronal buffered saline (GPS-EDTA) for
30 min at 37°C. Alternatively, GPS-EDTA was replaced with buffer containing C3 and each terminal component (C5-C9). In a single-step hemolysis
assay, EA were incubated with an 80- or 160-fold dilution of C4-deficient GPS
supplemented with human C4 that was preincubated with DENV NS1 for
30 min at 37°C. In some experiments, C1 inhibitor (C1-INH; 40 µg/ml) was
added to before the incubation with EA and C4-deficient GPS. After centrifugation, erythrocyte lysis was assayed in the supernatant by spectrophotometry
at 414 nm.
For preclearing experiments DENV NS1 was incubated with anti-NS1
(2G6) or anti-E (4G2; negative control) Sepharose beads for 4 h at 4°C. The
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attenuate complement activation during secondary infection. Such an interaction at endothelial or serosal sites could
trigger dysfunctional complement responses by NS1-Ab
immune complexes that promote fluid extravasation into
pleural and peritoneal spaces, a characteristic of DHF/DSS
(Nimmannitya, 1987). Alternatively, antagonism of C4 function by NS1 may have a more important role in primary
Flavivirus infection by enhancing the infectivity of virus in
serum or tissues, which otherwise can be neutralized by complement. An improved understanding of the novel immune
evasion mechanisms of Flavivirus NS1 will likely foster
insight into the host-pathogen interactions that modulate
disease severity.
In summary, our results point to formation of a complex
of soluble NS1 with human C1s and C4. This complex
promotes cleavage by C1s of C4 to C4b and thereby limits
the supply of native C4 to participate in complement activation at the infectious site. NS1 derived from at least three
clinically important Flaviviruses, DENV, WNV, and YFV,
possesses this immune evasion activity for the human complement system.
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C4b cofactor activity assay
Purified soluble complement receptor-1 (sCR1) was a gift (H. Marsh,
Avant Immunotherapeutics, Inc., Needham, MA). Recombinant MCP
was generated as previously described (Liszewski et al., 2006). C4b was incubated with purified DENV NS1 or WNV NS1 or BSA for 1 h at 4°C.
Subsequently, factor I, with or without a cofactor (C4BP or sCR1 or
MCP), was added to the C4b-NS1 solution. After a 2-h incubation at
37°C, reducing sample buffer was added, and the fragments of C4b were
separated on 10% SDS-PAGE. Western blot was performed using an antiC4d mAb (Quidel) and a HRP-conjugated anti–mouse IgG.

C3b and C4b deposition on erythrocyte cell surface
EAC1 was prepared as described above. Human C4 was incubated with
purified DENV NS1 or C4BP for 1 h on ice before adding EAC1. After a
15-min incubation at 30°C, EAC14b were sequentially incubated with C2
and C3 as described above. The deposition of C3b and C4b was determined by staining with anti-C3c and anti-C4c mAbs, respectively. After
three washes, cells were incubated with Alexa Fluor 647–conjugated anti–
mouse IgG and analyzed by flow cytometry.

Complement activation on the surface of CHO cells
This assay was modified from the published protocols (Barilla-LaBarca
et al., 2002; Liszewski et al., 2008) and performed in 96-well plates seeded
with 106 cells/well. CHO cells were sensitized with 50 µg/ml rabbit antiCHO surface antigen IgG at 4°C on a shaker (600 rpm). After a 30 min
incubation, the cells were incubated with the mixture of DENV NS1
or BSA (25 µg/ml) and purified human CP complement component C1
(2.5 µg/ml), C2 (2 µg/ml), C3 (10 µg/ml), and C4 (6.67 µg/ml) in
GVB2+ buffer for 45 min at 4°C on a shaker. Deposition of C3d and C4d
was detected by flow cytometry as described above with a murine mAb to
human C3d or C4d (10 µg/ml; Quidel).

Assessment of C4 cleavage
Western blot. C4 was incubated with NS1 on ice for 1 h. In some experiments, purified C1qrs or C1s was added to an NS1-C4 mixture. At various time points, reducing sample buffer was added, and samples were
separated by 10% SDS-PAGE. Western blot was performed using goat
anti–human C4 Ab as described above.
C4a ELISA. Purified C4 was incubated with purified NS1 in the presence
or absence of C1-INH (40 µg/ml) on ice for 1 h. After a second 1 h incubation at 37°C, C4a was measured with the BD OptEIA Human C4a
ELISA kit (BD).
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Direct interaction of NS1 and C1s
Size exclusion chromatography. Purified WNV NS1 (50 µg) or human
proC1s (15 µg) or Fab fragment of murine mAb to WNV E protein (E9-Fab;
15 µg) in PBS was fractionated in a Superose 6 column (GE Healthcare) at a
rate of 0.5 ml/min. 15 fractions (1 ml each) were collected and concentrated
10-fold by 0.5 ml centrifugal filter devices (Amicon Ultra; Millipore) before
SDS-PAGE and Western blot with biotinylated anti-WNV NS1 mAb 3NS1
(0.5 µg/ml; Chung et al., 2006b) followed by HRP-conjugated streptavidin
(1:5,000; Vector Laboratories) or goat antiserum to human C1s (1:5,000;
Quidel) followed by donkey anti–goat IgG (1:5,000; Sigma-Aldrich), and
HRP-conjugated goat anti–mouse IgG (Sigma-Aldrich; 1:5,000). In some
experiments, WNV NS1 was preincubated with proC1s or E9-Fab for 1 h
on ice before loading onto a size exclusion column.
ELISA. Microtiter plates were coated with purified human C1s or proC1s
or BSA (10 µg/ml in PBS). After five washes with PBS, nonspecific binding
sites were blocked with 2% heat inactivated BSA in PBS for 2 h at room
temperature followed by five washes with PBS. Purified WNV, DENV,
or YFV NS1 at various concentrations was added to each well and incubated
for 2 h at room temperature. Bound WNV or DENV NS1 was detected
as described above. A 1:700 dilution of ascites fluid containing the YFV
specific anti-NS1 mAb 4E3 (Schlesinger et al., 1985) was used to detect
YFV NS1.

Serum neutralization of DENV
Neutralization of DENV by C4-deficient GPS, with and without reconstitution with human C4 and in the presence or absence of DENV NS1 protein, was tested in a plaque assay using BHK-21 cells. Human C4 was
incubated with soluble DENV NS1 or BSA (final protein concentration of
50 µg/ml, diluted in gelatin veronal buffer with Mg2+ and Ca2+ [GVB2+];
CompTech) for 1 h at room temperature. DENV2 strain 16681 (2 × 102
PFU) was then added to the mixture of NS1-C4 or BSA-C4, followed by
C4-deficient GPS, either untreated or heat inactivated (56°C for 30 min)
diluted in GVB2+ buffer to a final serum concentration of 10%. Samples were
incubated for 1 h at 37°C and then added to BHK-21 monolayers in
duplicate. Infection of BHK-21 cells occurred for 90 min at 37°C; after that
the cells were washed extensively with DMEM, overlaid with 1% agarose in
Minimal Essential Media supplemented with 2% FBS, and cultured for five
days at 37°C. After formaldehyde fixation (10% vol/vol) and staining
of wells with a 1% (wt/vol) crystal violet solution in 20% ethanol, plaques
were counted.

Statistical analysis
Datasets were compared by a two-tailed, unpaired Student’s t test. Multiple
comparisons were performed using an analysis of variance test. Statistical
significance was achieved when P values were <0.05.

Online supplemental material
Using preclearance experiments, Fig. S1 shows that the inhibitory activity
against C4 in a hemolysis assay is NS1-dependent. Fig. S2 demonstrates that
NS1 lacks the ability to regulate C3 convertase or C3 and C5 decay accelerating activity. Fig. S3 shows that NS1 lacks cofactor activity for factor I to
degrade C4b. Fig. S4 establishes that the ability of NS1 to promote C4 degradation is specific as proteolysis of C3 was not observed. Fig. S5 provides an
analysis of WNV NS1 by SDS-PAGE and Western blot after purification by
immunoaffinity and ion-exchange chromatography. Fig. S6 presents an analysis of WNV NS1 by SDS-PAGE and Western blot after purification by size
exclusion chromatography. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20092545/DC1.
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quantity of DENV NS1 after preclearing was analyzed by Western blot. The
precleared solutions also were subjected to a single-step hemolysis assay.
The assay for decay-accelerating activity was performed essentially as
previously described (Krych-Goldberg et al., 2005). To prepare the CP C3
convertase, EAC14b were incubated for 4 min at room temperature with
C2; for the CP C5 convertase, cells were incubated under the same conditions with C2 and C3. EAC14b2a or EAC14b2a3b were incubated with
purified DENV NS1, sCR1, or C4BP for 10 min at 30°C. Subsequently,
GPS-EDTA was added and hemolysis was determined.
To test for the activity of Flavivirus NS1 to enhance C1s/proC1s
activity, purified WNV, DENV, and YFV NS1 (20 µg/ml) was incubated
with C1s (0.04 µg/ml) or proC1s (0.4 µg/ml) on ice. After a 1-h preincubation, C4 (4µg/ml) was added to the NS1-C1s/proC1s mixture and
incubated for 1 h on ice. 50 µl of EA (8 × 106 cells) and 500 µl of a 160fold dilution of C4-deficient GPS were added and incubated for 30 min at
37°C, and then hemolysis was determined. In some experiments, purified
YFV NS1 (20 µg/ml) was incubated with proC1s (0.2 µg/ml) for 1 h on
ice. Purified human C4 (2.5 µg/ml) was then added to NS1-proC1s mixture and incubated for 0, 5, 15, 30, 45, and 60 min at room temperature
followed by the addition of EA- and C4-deficient GPS as described in the
first paragraph of this section.
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